Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
DBV Technologies S.A. (DBVT) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/31/2023 8-K Quarterly results
05/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin ™ Peanut in Toddlers"
05/04/2023 8-K Quarterly results
Docs: "2023 2022 Variation Net income / -3.8 -23% Basic / diluted net income / per share +0.1 +27% Net result for the three months ended March 31, 2023 is a loss amounting to $20.5 million, compared to a loss amounting to $16.7 million for the same period in 2022. On a per share basis, net loss is $0.22 for the three months ended March 31, 2023. CONDENSED STATEMENT OF CONSOLIDATED FINANCIAL POSITION In millions of USD Assets 232.9 246.5 of which cash & cash equivalents 192.3 209.2 Liabilities 53.8 52.1 Shareholders' equity 179.1 194.5 of which net result CONDENSED STATEMENT OF CONSOLIDATED OPERATIONS AND COMPREHENSIVE LOSS In millions of USD Three months ended March 31, 2023 2022 Revenues 2.2 2.5 Research & Development Sales & Marketing General & Administrative Restructuring income/ - Oper..."
03/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"V"
12/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial"
11/03/2022 8-K Quarterly results
10/04/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors"
08/01/2022 8-K Quarterly results
Docs: "Three months ended June 30, Six months ended June 30, Six months ended June 30, 2022 2021 2022 2021 2022 2021 Net $ $ $ $ $ $ Basic / diluted net loss per share $ $ $ $ $ $ For the three months ended June 30, 2022, net loss was $ million compared to a net loss of $ million for the comparable period in 2021. On a per share basis, net loss was $ and $ for the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022, net loss was $ million and $ million under U.S. GAAP and IFRS, respectively. Net loss per share was $ under U.S. GAAP and $ under IFRS. Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of June 30, 2022: Total number of shares Total number of voting rights 06/30/2022 94,022,679 Tota..."
06/13/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
03/09/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
12/20/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"DBV Technologies Provides Update on Investigational Viaskin ™ Peanut DBV Technologies S.A. , a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical study for a modified Viaskin ™ Peanut patch in children in the intended patient population. The Company also issued an update on the Marketing Authorization Application for Viaskin Peanut with the European Medicines Agency . U.S. Regulatory Update:"
10/26/2021 8-K Quarterly results
Docs: "DBV Technologies Reports Third Quarter 2021 Financial Results and Recent Regulatory Developments DBV Technologies S.A. , a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2021. The quarterly financial statements were approved by the Board of Directors on October 26, 2021. The Company also provided regulatory updates from the U.S. Food and Drug Administration and European Medicines Agency for Viaskin ™ Peanut. US Regulatory Update: On October 14, 2021, DBV received communication from the FDA concerning the STAMP protocol submission of May 6, 2021. The FDA has requested a stepwise approach to DBV's modified Viaskin Peanut development program. The FDA would like to review the data from DBV's protein uptake release study prior to providing ad..."
08/02/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 August 2, 2021 Date of Report DBV Technologies S.A. France 001-36697 Not applicable 177-181 avenue Pierre Brossolette 92120 Montrouge France Not Applicable Registrant's telephone number, including area code: +33 1 55 42 78 78 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Ac...",
"Business Highlights:"
05/24/2021 8-K Quarterly results
05/03/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
04/02/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
01/21/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 January 14, 2021 Date of Report DBV Technologies S.A. France 001-36697 Not applicable 177-181 avenue Pierre Brossolette 92120 Montrouge France Not Applicable Registrant's telephone number, including area code: +33 1 55 42 78 78 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange ..."
01/14/2021 8-K Quarterly results
01/07/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy